Abstract
Protein S is a natural anticoagulant. Congenital protein S (PS) deficiency is a confirmed risk factor of venous thromboembolism (DVT) which though occurs infrequently yet is a leading cause of maternal mortality and morbidity. Congenital PS deficiency may also be responsible for obstetric complications such as preeclampsia/eclampsia, recurrent fetal loss and intrauterine fetal restriction. Congenital PS deficiency has been identified in 1-7.5 % of patients with DVT and in 0.03-0.13 % general Caucasian population. However, Japanese people have higher prevalence both in VTE patients (12.7 %) and general population (0.48-0.63 %). Because PS deficiency is the most frequent congenital thrombophilia in Japanese people, Japanese obstetricians must understand this thrombophilia and also that women with PS deficiency have an increased risk of VTE and a necessity of prophylactic use of anticoagulant against recurrent VTE during pregnancy and puerperium. This article reviews the literature to understand PS and congenital PS deficiency, especially the association of this thrombophilia with pregnancy.
Keywords: protein s deficiency, venous thromboembolism, pregnancy, obstetric complications
Current Drug Targets
Title: Protein S and Congenital Protein S Deficiency: The Most Frequent Congenital Thrombophilia in Japanese
Volume: 6 Issue: 5
Author(s): Tomoko Adachi
Affiliation:
Keywords: protein s deficiency, venous thromboembolism, pregnancy, obstetric complications
Abstract: Protein S is a natural anticoagulant. Congenital protein S (PS) deficiency is a confirmed risk factor of venous thromboembolism (DVT) which though occurs infrequently yet is a leading cause of maternal mortality and morbidity. Congenital PS deficiency may also be responsible for obstetric complications such as preeclampsia/eclampsia, recurrent fetal loss and intrauterine fetal restriction. Congenital PS deficiency has been identified in 1-7.5 % of patients with DVT and in 0.03-0.13 % general Caucasian population. However, Japanese people have higher prevalence both in VTE patients (12.7 %) and general population (0.48-0.63 %). Because PS deficiency is the most frequent congenital thrombophilia in Japanese people, Japanese obstetricians must understand this thrombophilia and also that women with PS deficiency have an increased risk of VTE and a necessity of prophylactic use of anticoagulant against recurrent VTE during pregnancy and puerperium. This article reviews the literature to understand PS and congenital PS deficiency, especially the association of this thrombophilia with pregnancy.
Export Options
About this article
Cite this article as:
Adachi Tomoko, Protein S and Congenital Protein S Deficiency: The Most Frequent Congenital Thrombophilia in Japanese, Current Drug Targets 2005; 6 (5) . https://dx.doi.org/10.2174/1389450054545980
DOI https://dx.doi.org/10.2174/1389450054545980 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Medicinal Chemistry Reviews - Online (Discontinued) Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Antiplatelet Agents and Anticoagulants in Patients with Chronic Kidney Disease - from Pathophysiology to Clinical Practice
Current Pharmaceutical Design New Anticoagulants: Focus on Venous Thromboembolism
Current Vascular Pharmacology Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Pharmacological Strategies for Inhibition of Thrombin Activity
Current Pharmaceutical Design Heart Failure in East Asia
Current Cardiology Reviews Pericytes Within A Pulmonary Neurovascular Unit in Coronavirus Disease 2019 Elicited Pathological Changes
Current Neurovascular Research Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Symposium Introduction
Current Cardiology Reviews Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Current Reviews on Renal Vein Thrombosis in Neonates
Current Pediatric Reviews Inherited Coagulation Factor VII and X Deficiencies Associated with Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology
Current Genomics Pharmacological Prevention of Peri-, and Post-Procedural Myocardial Injury in Percutaneous Coronary Intervention
Current Cardiology Reviews Stroke Prevention in Atrial Fibrillation: Concepts and Controversies
Current Cardiology Reviews